Opioids and the Skin: “Itchy” Perspectives beyond Analgesia and Abuse  by Schmelz, Martin & Paus, Ralf
COMMENTARY
 www.jidonline.org 1287
and secretion of an elastase inhibitor 
following an insult (excessive UV light) 
makes sense. Chronic exposure to UV 
light would cause sustained production 
of elafin, and the action of transgluta-
minases will result in an irreversible 
covalent binding with elastic fibers.
Although this would position the 
protease inhibitor in exactly the right 
place to do its job, it also comes with 
a cost: modification of glutamines and 
lysines in the elastic fiber constituents. 
Accumulation of these modifications 
could in the end severely compromise 
the biochemical and cell-biological 
properties of these elastic fibers, includ-
ing resistance to breakdown and nor-
mal turnover, propensity to aggregate, 
and activation of fibroblasts to increase 
tropoelastin synthesis. The assertion 
by Muto et al. (2007) that fiber-associ-
ated elafin protects against breakdown 
does not, in itself, explain why there is 
a strong increase of elastic fiber material 
in photodamaged skin. There are, how-
ever, some lessons to be learned from a 
mouse model. Chronic UV irradiation 
of hairless mice is a model for actinic 
elastosis (Starcher and Conrad, 1995). 
It was shown, however, that mice that 
lack neutrophil elastase do not accumu-
late elastic fibers; this suggests a role for 
elastase not only in breakdown but also 
in increased production of elastic fibers. 
There is no mouse ortholog for the 
human elafin gene, but mice do have 
SLPI, which probably has the same func-
tion. Taken together, these observations 
suggest that elastase activity promotes 
elastin synthesis, possibly in an indi-
rect way following the release of break-
down products of the elastic fibers. This 
process could be controlled to some 
extent by the local induction of elastase 
inhibitors such as elafin (Muto et al., 
2007) and SLPI (Wingens et al., 1998). 
When these safeguards fail, excess 
elastase activity cannot be controlled. 
Speculatively, elastic fibers altered by 
transglutaminase-mediated cross-linking 
and increased elastin production will 
in the end lead to the elastotic material 
seen in photodamaged skin.
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Opioids and the Skin: “Itchy” 
Perspectives beyond Analgesia and 
Abuse
Martin Schmelz1 and Ralf Paus2
Opioids are intimately linked to central pain inhibition and their abuse poten-
tial. Thus, peripheral opioid receptors in the skin have been studied initially with 
a focus on their peripheral analgesic properties. Recent results, however, clearly 
indicate that opioids play a specific role in skin homeostasis by modulating kera-
tinocyte differentiation, wound healing, and inflammatory responses.
Journal of Investigative Dermatology (2007) 127, 1287–1289. doi:10.1038/sj.jid.5700634
Traditionally, opioid research is 
focused on the powerful inhibition of 
central pain pathways by opioid recep-
tor ligands, an effect that has been clin-
ically exploited for centuries. Like the 
habitual abuse of exogenous opioids 
— a matter of much scientific scrutiny 
and heated political debate — analge-
sic therapy with exogenous opioids has 
long been known to be associated with 
intense generalized pruritus (Twycross 
et al., 2003; Gutstein and Akil, 2001). 
And yet, this ancient lead toward the 
peripheral activities of opioids has 
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only relatively recently been followed 
up. However, even after the detection 
of peripheral opioid receptors, again, 
research tended to focus on periph-
eral analgesic effects of opioids (Stein 
et al., 2003), whereas investigations 
on opioid effects beyond analgesia 
retained their status as rare orchids in 
a jungle of pain research (for example, 
Braz et al., 2001).
With the discovery that defined epi-
thelial-cell populations in mammalian 
skin itself generate endogenous opio-
ids, such as β-endorphin (Slominski et 
al., 1992), and use them to modulate 
multiple different functions (for exam-
ple, control of hair growth and pigmen-
tation (Furkert et al., 1997; Tobin and 
Kauser, 2005)), and that wound heal-
ing and differentiation in mice are also 
opioid receptor-regulated phenomena 
(Bigliardi-Qi et al., 2006), one cannot 
but consider the skin a “habitual opioid 
user.” We are just beginning to under-
stand which stimuli induce epidermal 
opioid release such as cannabinoid 
receptor (CB2) activation (Ibrahim et 
al., 2005) but are still struggling to fig-
ure out what our skin is using these 
opioids for.
Bigliardi-Qi et al. (2007, this issue) 
now open a new perspective on the 
role of opioid signaling in the epi-
dermis that is unrelated to pain or 
ana lgesia, yet relevant to our slowly 
evolving understanding of the patho-
genesis of itch (Paus et al., 2006a; 
Steinhoff et al., 2006). These authors 
found that µ- and κ-opioid receptor 
knockout mice have a markedly thin-
ner epidermis. Moreover, inflamma-
tory changes induced by a combined 
acetone/ether and water application 
were reduced in both knockout mice. 
This supports the notion of an intimate 
link of opioid signaling in the regula-
tion of inflammatory processes. Topical 
application of acetone/ether and water 
not only disrupts the epidermal barrier 
but also provokes epidermal hypertro-
phy and scratch behavior (Miyamoto et 
al., 2002; Nojima et al., 2004) — even 
though this is not accompanied by a 
significant influx of inflammatory cells 
in the treated skin areas (as Bigliardi-Qi 
et al. (2007) confirm).
Examining the interaction of kerati-
nocytes and peripheral nerves histo-
logically, the authors found that the 
persistent growth of keratinocytes in 
the epidermis forces the most super-
ficially located C-fibers to constantly 
extend their endings (Bigliardi-Qi et 
al., 2007). However, in peripheral sen-
sory neuropathy, epidermal nerve fib-
ers might no longer be able to keep 
up with the sustained hyperprolifera-
tion of keratinocytes and, thus, might 
end up terminating abruptly at the 
dermoepidermal junction in diabetes 
patients (Kennedy et al., 2005). A simi-
lar mismatch can result from acetone/
ether-induced epidermal hypertro-
phy, which leaves the intraepidermal 
nerves “stretched” in appearance and 
more sparse (Bigliardi-Qi et al., 2006). 
It is interesting to note that, in both 
situations, the ratio of keratinocytes to 
nerves increases, which may result in a 
higher availability of neurotrophins to 
the epidermal nerve fibers, thus lead-
ing also to sensitization of their end-
ings (Griffin, 2005).
Therefore, the current study illumi-
nates a novel aspect of the interaction 
between keratinocytes and peripheral 
nerves: whereas earlier work has mainly 
studied the consequences of impaired 
nerves for primarily normal epidermal 
function (Li et al., 1997), Bigliardi-Qi et 
al. (2007) have studied the response of 
primarily normal epidermal nerve fib-
ers to experimentally induced epider-
mal hyperproliferation.
This is where the story becomes 
“itchy.” Pruritus can be reduced by 
painful stimuli, but vice versa, spi-
nally administered µ-opioid agonists 
can induce segmental analgesia, 
often combined with segmental pruri-
tus. Conversely, κ-opioid antagonists 
enhance itch in animal models (Kamei 
and Nagase, 2001), and the κ-opioid 
agonist nalbuphine reduces µ-opioid-
induced pruritus in humans (Kjellberg 
and Tramer, 2001), as does a newly 
developed κ-opioid agonist (Wikstrom 
et al., 2005).
From these results, one would have 
expected increased scratch behavior 
in the κ-opioid receptor-deficient mice 
and reduced scratching in the µ-defi-
cient. Indeed, the authors found some 
reduction in scratching behavior in the 
µ-opioid receptor knockout mice, but 
a similar trend toward less scratching 
was also evident in the κ-opioid recep-
tor-knockout mice (Bigliardi-Qi et al., 
2007). In contrast, reduced scratching 
behavior matched the reduced epi-
dermal hypertrophy in response to the 
acetone/ether stimulus in both opioid 
receptor knockout strains. Therefore, 
reduced scratching might well be sec-
ondary to the intriguing anti-inflamma-
tory effects seen in the opioid receptor 
knockout mice, rather than indicat-
ing an independent peripheral pruritic 
effect of opioids.
However, irrespective of whether or 
not independent, opioid receptor-medi-
ated pruritus-inducing pathways exist, 
the study by Bigliardi-Qi et al. (2007) 
strongly encourages a more systematic 
exploration of the evidently important 
and multifaceted, yet still lamentably 
underinvestigated, functions of periphe-
ral opioid receptor signaling in skin 
biology and pathology. The pertinence 
of such opioid research beyond the 
analgesia horizon is strikingly illustrat-
ed by the recently discovered role of 
µ- and κ-opioid receptors in neuropro-
tection and in the neuronal differen-
tiation of stem cells (Kim et al., 2006; 
Narita et al., 2006). It is further sup-
ported by the apparent correlation of 
the β-endorphin serum level with the 
clinical severity of a chronic inflamma-
tory, intensely pruritic skin disease such 
as atopic dermatitis (Lee et al., 2006).
Thus, the time has come to advocate 
a careful dissection of the role of opi-
oid receptor-mediated signaling in the 
promotion of inflammation- and itch-
perpetuating neuro-endocrine-immune 
signaling loops in the skin (Paus et al., 
2006a; Paus et al., 2006b). Nowhere 
are the peripheral functions of endoge-
nous opioids and their cognate recep-
tors in general — of which we probably 
have only scratched the surface — more 
amenable to analysis and therapeutic 
manipulation than in skin.
|
 A new perspective 
on the role of opioid 
signaling in the 
epidermis that is 
unrelated to pain or 
analgesia.
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Clues from Alopecia Areata on 
the Role of Neuropeptides in the 
Initiation of Autoimmunity
Richard S. Kalish1
A fascinating question regarding the pathogenesis of alopecia areata is the 
potential linkage with the brain. Siebenharr et al. demonstrate that substance 
P fibers are increased in early lesions, and that substance P treatment induces 
catagen follicles along with activated CD8+ T cells. Potentially, neuropeptides 
serve as the initial insult resulting in loss of tolerance and autoimmune disease.
Journal of Investigative Dermatology (2007) 127, 1289–1291. doi:10.1038/sj.jid.5700655
In this issue of the Journal of Investigative 
Dermatology, Siebenharr et al. (2007) 
present data strongly suggesting a role 
for substance P in alopecia areata. This 
is of great interest because it provides a 
potential link between brain and body 
with respect to the initiation of autoim-
mune disease. There is considerable 
evidence supporting an autoimmune 
pathogenesis for alopecia areata (Gilhar 
and Kalish, 2006). Alopecia areata has 
a statistical association with autoim-
mune thyroiditis and HLA DQB1*03. 
Histologically, the condition is marked 
by an infiltrate of lymphocytes around 
hair follicles, associated with prema-
ture catagen, and conversion of termi-
nal hairs to miniature anagen hairs. The 
hair follicle demonstrates evidence of 
immune activation including expression 
of major histocompatibility complex 
(MHC) class I and class II molecules as 
well as ICAM-1 on follicular epithelium, 
where these molecules are usually poor-
ly expressed or absent. The T-cell infil-
trate is characterized by perifollicular 
CD4+ cells and intrafollicular CD8+ cells 
as well as a T-helper 1 cytokine profile. 
Immunologic intervention such as treat-
ment with allergic contact sensitizers 
can induce hair regrowth, supporting a 
role of immunology in the pathogenesis.
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